![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis
-
Media ReleaseNovartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
-
Media ReleaseNovartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
-
Media ReleaseNovartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
-
Media ReleaseNovartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
-
Media ReleaseNovartis set to achieve 100% renewable electricity in its European operations
-
Media ReleaseNovartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media ReleaseNovartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
-
Media ReleaseNovartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 28
- › Next page